Hemispherx Biopharma Inc (HEB)
0.21USD
21 May 2013
$0.00 (+0.87%)
$0.21
$0.20
$0.21
$0.20
683,182
541,592
$1.10
$0.18
HEB
About
Overall
| Beta: | 1.24 |
| Market Cap (Mil.): | $34.47 |
| Shares Outstanding (Mil.): | 167.23 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| HEB | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 54.65 | 35.85 |
| EPS (TTM): | -0.12 | -- | -- |
| ROI: | -41.57 | 0.83 | 18.76 |
| ROE: | -41.99 | 1.79 | 19.57 |
Hemispherx says FDA rejects fatigue drug application
- Hemispherx Biopharma Inc said U.S. regulators had declined to approve its new drug application for Ampligen, its experimental drug for treating chronic fatigue syndrome, five years after the company first filed for the drug's approval.
Hemispherx says FDA rejects fatigue drug application
Feb 4 - Hemispherx Biopharma Inc said U.S. regulators had declined to approve its new drug application for Ampligen, its experimental drug for treating chronic fatigue syndrome, five years after the company first filed for the drug's approval.
Competitors
| Price | Change | |
|---|---|---|
| Pfizer Inc. (PFE.N) | $28.75 | +0.05 |
| Novartis AG (NOVN.VX) | CHF72.40 | +0.65 |
| Merck & Co., Inc. (MRK.N) | $46.87 | +1.66 |
| AstraZeneca plc (AZN.L) | 3,394.50p | +4.00 |
| GlaxoSmithKline plc (GSK.L) | 1,742.00p | +20.50 |
| Baxter International Inc. (BAX.N) | $73.02 | +0.08 |
| Genta Incorporated (GNTAQ.PK) | $0.00 | +0.00 |
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: GlobalData
|
$250.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: TheStreet.com Ratings
|
$10.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
